id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0862-0219,FDA,FDA-2021-N-0862,Reference 10 - FDA Combination Products web page,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2025-02-23T18:35:38Z,,0,0,090000648688c405
FDA-2021-N-0862-0226,FDA,FDA-2021-N-0862,Reference 18 - 73 FR 63491_Docket FDA-2008-N-0549_10-24-2008,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T20:00:49Z,,0,0,090000648688c497
FDA-2021-N-0862-0227,FDA,FDA-2021-N-0862,Reference 19 - 83 FR 40973_Docket FDA-2017-N-6730_08-17-2018,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T20:00:54Z,,0,0,090000648688c4a8
FDA-2021-N-0862-0215,FDA,FDA-2021-N-0862,Reference 7a - NPSA_Guide to Graphic Design of Medication Packaging 2nd Ed_2007,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:59:19Z,,0,0,090000648688c3cb
FDA-2021-N-0862-0218,FDA,FDA-2021-N-0862,Reference 9 - FDA eCTD Resources web page,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2025-02-23T18:35:38Z,,0,0,090000648688c403
FDA-2021-N-0862-0223,FDA,FDA-2021-N-0862,Reference 15 - 83 FR 13394_Docket FDA-2008-N-0549_04-02-2018,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T20:00:19Z,,0,0,090000648688c490
FDA-2021-N-0862-0225,FDA,FDA-2021-N-0862,Reference 17 - 87 FR 68702_Docket FDA-2022-N-2673_11-16-2022,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T20:00:41Z,,0,0,090000648688c493
FDA-2021-N-0862-0220,FDA,FDA-2021-N-0862,Reference 11 - MOU Between the FTC and FDA Concerning the Exchange of Information (FDA-225-71-8003)_April 1971,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:59:53Z,,0,0,090000648688c406
FDA-2021-N-0862-0217,FDA,FDA-2021-N-0862,Reference 8 - USP_Recommendations to the Safe Medication Use Expert Committee by the Health Literacy and Prescription Container Labeling Advisory Panel_2010,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:59:32Z,,0,0,090000648688c402
FDA-2021-N-0862-0208,FDA,FDA-2021-N-0862,Reference List - Nonprescription Drug Product With an Additional Condition for Nonprescription Use - Final Rule,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:58:28Z,,0,0,090000648688c868
FDA-2021-N-0862-0207,FDA,FDA-2021-N-0862,Nonprescription Drug Product With an Additional Condition for Nonprescription Use,Rule,Final Rule,2024-12-26T05:00:00Z,2024,12,2024-12-26T05:00:00Z,,2024-12-26T15:41:32Z,2024-30261,0,0,090000648688bfbc
FDA-2021-N-0862-0216,FDA,FDA-2021-N-0862,Reference 7b - NPSA_Guide to Labelling and Packaging of Injectable Medicines_1st Ed_2007,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:59:23Z,,0,0,090000648688c3cc
FDA-2021-N-0862-0209,FDA,FDA-2021-N-0862,Reference 1 - FDA Guidance for Industry_Label -Comprehension-Studies-for-Nonprescription-Drug-Products_Aug2010,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:58:33Z,,0,0,090000648688c8ae
FDA-2021-N-0862-0212,FDA,FDA-2021-N-0862,Reference 4 - FDA Guidance for Industry and FDA Staff_Policy for Device Software Functions and Mobile Medical Applications,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:58:49Z,,0,0,090000648688c8b3
FDA-2021-N-0862-0213,FDA,FDA-2021-N-0862,Reference 5 - FDA Medwatch The FDA Safety Information and Adverse Event Reporting Program,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2025-02-23T18:35:38Z,,0,0,090000648688c3c7
FDA-2021-N-0862-0221,FDA,FDA-2021-N-0862,Reference 12 - FDA Prescription to Over-the-Counter (OTC) Switch List web page,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2025-02-23T18:35:37Z,,0,0,090000648688c407
FDA-2021-N-0862-0211,FDA,FDA-2021-N-0862,Reference 3 - FDA Guidance for Industry_Application of Human Factors Engineering Principles for Combination Products QA_Sept2023,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:58:45Z,,0,0,090000648688c8b1
FDA-2021-N-0862-0222,FDA,FDA-2021-N-0862,Reference 14 - 87 FR 38313_Docket FDA-2021-N-0862_06-28-2022,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T20:00:08Z,,0,0,090000648688c986
FDA-2021-N-0862-0224,FDA,FDA-2021-N-0862,Reference 16 - 70 FR 52050_Docket 2005N-0345_09-01-2005,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T20:00:32Z,,0,0,090000648688c491
FDA-2021-N-0862-0210,FDA,FDA-2021-N-0862,Reference 2 - FDA Guidance for Industry_Self-Selection-Studies-for-Nonprescription-Drug-Products_April2013,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2024-12-26T19:58:41Z,,0,0,090000648688c8b0
FDA-2021-N-0862-0214,FDA,FDA-2021-N-0862,Reference 6 - FDA Consumer Complaint Coordinators web page,Supporting & Related Material,Background Material,2024-12-26T05:00:00Z,2024,12,,,2025-02-23T18:35:38Z,,0,0,090000648688c3c8